Is Black Garlic Cholesterol Randomized Trial safe?

Updated October 2026

Quick Answer

Black Garlic Cholesterol Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Background Aged black garlic (ABG) is rich in organosulfur compounds such as S-allyl-cysteine (SAC) and may influence lipid metabolism, although evidence from controlled trials remains limited.

Key Takeaways

  • 01Background Aged black garlic (ABG) is rich in organosulfur compounds such as S-allyl-cysteine (SAC) and may influence lipid metabolism, although evidence from controlled trials remains limited. [Serrano JCE (2026)]
  • 02In secondary exploratory analyses of NMR-derived lipoprotein subclasses, nominally significant differences were observed: ABG was associated with a reduction in the total number of particles and HDL particles. [Serrano JCE (2026)]
  • 03Conclusion Low-dose ABG supplementation did not significantly modify conventional lipid markers in Grade I hypertensive individuals. [Serrano JCE (2026)]
  • 04The aim of this study was to evaluate the impact of a low-dose SAC-optimized ABG on blood lipid profiles in Grade I hypertensive individuals. [Serrano JCE (2026)]
The current Migaku evidence database contains 2 reusable source documents for Black Garlic Cholesterol Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Background Aged black garlic (ABG) is rich in organosulfur compounds such as S-allyl-cysteine (SAC) and may influence lipid metabolism, although evidence from controlled trials remains limited. [Serrano JCE (2026); evidence level 2] - In secondary exploratory analyses of NMR-derived lipoprotein subclasses, nominally significant differences were observed: ABG was associated with a reduction in the total number of particles and HDL particles. [Serrano JCE (2026); evidence level 2] - Conclusion Low-dose ABG supplementation did not significantly modify conventional lipid markers in Grade I hypertensive individuals. [Serrano JCE (2026); evidence level 2] - The aim of this study was to evaluate the impact of a low-dose SAC-optimized ABG on blood lipid profiles in Grade I hypertensive individuals. [Serrano JCE (2026); evidence level 2] - 1 2 3 4 5 6 6 Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, refers to excessive accumulation of fat in the liver, accompanied by at least one cardiometabolic risk factor (i.e., overweight/obesity, abnormal glucose metabolism, elevated blood pressure, elevated triglycerides, and reduced high-density lipoprotein cholesterol) []. [Sun Niuniu (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Effects of aged black garlic (ABG10+<sup>®</sup>) on lipoprotein subclass composition in Grade I hypertension: a randomized, triple-blind controlled trial with sex-stratified sequential allocation.
  2. Protective Effects of Allicin and Garlic-Derived Interventions Against Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Evidence and Mechanistic Insights